Volume 125, Issue 1 , Pages 209-216, January 2010
Defect of regulatory T cells in patients with Omenn syndrome
Background
Omenn syndrome (OS) is an autosomal-recessive disorder characterized by severe immunodeficiency and T-cell–mediated autoimmunity. The disease is caused by hypomorphic mutations in recombination-activating genes that hamper the process of Variable (V) Diversity (D) Joining (J) recombination, leading to the generation of autoreactive T cells. We have previously shown that in OS the expression of autoimmune regulator, a key factor governing central tolerance, is markedly reduced.
Objective
Here, we have addressed the role of peripheral tolerance in the disease pathogenesis.
Methods
We have analyzed forkhead box protein P3 (FOXP3) expression in peripheral blood T cells of 4 patients with OS and in lymphoid organs of 8 patients with OS and have tested the suppressive activity of sorted CD4+ CD25high peripheral blood T cells in 2 of these patients.
Results
We have observed that CD4+CD25highT cells isolated ex vivo from patients with OS failed to suppress proliferation of autologous or allogenic CD4+ responder T cells. Moreover, despite individual variability in the fraction of circulating FOXP3+ CD4 cells in patients with OS, the immunohistochemical analysis of FOXP3 expression in lymph nodes and thymus of patients with OS demonstrated a severe reduction of this cell subset compared with control tissues.
Conclusion
Overall, these results suggest a defect of regulatory T cells in OS leading to a breakdown of peripheral tolerance, which may actively concur to the development of autoimmune manifestations in the disease.
Key words: Immunodeficiency, V(D)J recombination, Omenn syndrome, regulatory T cells, FOXP3, anergy and tolerance, thymus and the development of T lymphocytes
Abbreviations used: AIRE, Autoimmune regulator, FOXP3, Forkhead box protein P3, HD, Healthy donor, OS, Omenn syndrome, RAG, Recombination-activating gene, Treg, Regulatory T
This work was supported by grants from the Italian Telethon Foundation to A.V., from Fondazione Cariplo (Nobel project to A.V., and L.D.N./R.B.), Fondazione Cariplo to A.V. and P.L.P., EU grant FP7 HLH-cure (project n. 201461), PRIN 2007 n. 2007ACZMMZ_005, Telethon GGP07241 to R.B., grant FIRB/MIUR (n. RBIN04CHXT) to P.V., Ministero della Salute RF2007 Giovani Ricercatori Grant to C.S., and the Manton Foundation to L.D.N.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
PII: S0091-6749(09)01551-6
doi:10.1016/j.jaci.2009.10.023
© 2010 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 125, Issue 1 , Pages 209-216, January 2010
